Liquid biopsy
Liquid Biopsy for Early Diagnosis of Cancer, Monitoring Cancer, Companion Diagnostics, and Organ Transplant Rejection Monitoring without the Need for Tissue Biopsy
Liquid Biopsy, a non-invasive alternative to tissue biopsy, can help determine cancer treatments by identifying clinically relevant biomarkers.
Test
Advantages
-
No need to extract tissue samples
-
Minimizing Interpretation
-
Minimizing deviation
-
Detailed description for cancer treatment
Liquid biopsy can be used for early diagnosis (screening), recurrence of cancer (monitoring), and anticancer drug effect (companion diagnostics) using Circulating Tumor Cell* (CTC), a cfDNA derived from cancer cells. The cancer cell-derived cfDNA is analyzed through NGS technology and bioinformatics to see if there is a mutation that causes cancer, and whether it can be effective against the anticancer drug. It is a state-of-the-art personalized precision medical service that confirms whether there are cancer cells.*Circulating Tumor Cell (CTC): Cancer cells circulating in blood vessels
Test Options
Test Details
